China has become the first country in the world to approve a commercial brain-computer interface implant for treating paralysis, marking a significant milestone in the global race to bring this category of neurotechnology from research laboratories into the hands of patients. The implant, called NEO and developed by Neuracle Medical Technology, is designed to translate a patient’s thoughts directly into physical movement, and has been authorised for commercial sale by China’s National Medical Products Administration following 18 months of clinical testing and safety validation.
NEO is intended for patients aged 19 to 60 who have experienced paralysis resulting from spinal cord or neck injuries. The device is surgically implanted in the skull and employs a set of electrodes positioned on the brain’s motor cortex, the region responsible for controlling voluntary movement. When a user imagines performing a movement, the implant captures the corresponding neural signals and transmits them to an external processing system, which interprets those signals and converts them into commands for assistive devices such as a robotic glove. In practical terms, this allows users to perform fundamental daily tasks including grasping objects and handling utensils, functions that would otherwise be unavailable to individuals with severe motor impairment. Reported trial data indicates that 32 patients have already used the implant without experiencing any adverse side effects, providing an initial safety profile that satisfied the regulatory requirements for commercial authorisation.
The approval places China decisively ahead of other nations in the race to commercialise brain-computer interface technology. While development programmes are underway in several countries, the vast majority remain at the clinical trial stage and have yet to receive full regulatory clearance for commercial deployment. Elon Musk’s Neuralink, among the most prominent of the competing programmes, has not yet obtained approval for commercial sale. China’s advancement in this area is not incidental but strategic, backed by a government policy roadmap that outlines 17 specific steps aimed at establishing the country as a global leader in brain-computer interface research, development, and commercialisation within five years. The approval of NEO represents the first concrete commercial output of that strategy, signalling that China is moving at pace to translate policy ambition into market leadership in one of the most technically demanding and potentially consequential fields in modern medicine and human-machine interaction.
Follow the SPIN IDG WhatsApp Channel for updates across the Smart Pakistan Insights Network covering all of Pakistan’s technology ecosystem.
